Introduction
============

Urothelial carcinoma (UC), the predominant type among the varied histologic malignancies arising from the urinary tract, derives from the urothelial lining either in the lower tract (urinary bladder) or the upper tract (renal pelvis, ureter) [@B1], [@B2]. About 80% of patients with urinary bladder urothelial carcinoma face recurrence within one to two years of initial treatment [@B3], [@B4]. A significant proportion of these patients die because of recurrence even after receiving standard treatment [@B5]. In addition, around 25% of patients with UC have muscle-invasive disease, and either present with or later develop metastasis [@B6]. Thus effort is needed to explore the development and progression of UC in order to identify a better prognosticator and to enable better oncology-targeted therapies.

The majority deaths among cancer patients result from metastasis rather than the primary disease. Metastasis is the distal settlement of tumor cells and stats escaping from the primary location. Therefore we investigated genes related to cell motility in UC, which have not been systemically evaluated before. From data mining and comparison with other related genes, *SPOCK1* demonstrated exciting associations with invasiveness and metastasis in the transcriptome GSE31684.

*SPOCK1* encodes a calcium-binding matricellular glycoprotein belonging to the SPARC family [@B7]. The importance of SPARC in regulating proliferation, cell-cycle progression, apoptosis, adhesion, and cell-matrix interaction has been well documented [@B8]. Recent evidence suggests that SPOCK1, which is structurally similar, may play a crucial role in invasion of pilocytic astrocytoma [@B9] and in progression of hepatocellular carcinoma (HCC) [@B10]. Our study has found that SPOCK1 expression is correlated with adverse clinicopathological factors and survival in a well-characterized cohort of UC.

Materials and Methods
=====================

Data mining of the GEO to identify altered transcripts in UC
------------------------------------------------------------

One dataset, GSE31684 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31684>), which profiled radical cystectomy specimens from 93 urinary bladder urothelial carcinoma (UBUC) cases, was identified by data mining of the GEO (National Center for Biotechnology information, Bethesda, MD, USA) and by Affymetrix U133 Plus 2.0 Array. To evaluate the gene expression level, we imported the raw CEL files into the Nexus Expression 3 statistical software (BioDiscovery, EI Segundo, CA, USA). All probe sets were used in the evaluation without preselection or filtering. We performed supervised comparative analysis to examine the statistical significance of differentially expressed genes on the basis of progression in primary tumor status (pT) and the development of metastatic events. With this intention, we compared the differential expression in low-stage (pTa-pT1) UCs and muscle-invasive, high-stage (pT2-pT4) UCs, and compared non-metastatic lesions to those that developed distal metastasis, respectively, in order to perform functional profiles focusing on the genes related to cell motility (GO:0048870). Only genes displaying significantly differential expression in both stage (log2 ratio \> 1.0) and metastasis (log2 ratio \> 0.5) were enrolled for initial validation.

Patients and tumor specimens
----------------------------

This study was approved by the Institutional Review Board (IRB) of Chi Mei Medical Center, approval number IRB10302015. All specimens were obtained from the BioBank of Chi Mei Medical Center and had been collected previously following official ethical guidelines. We retrieved urothelial carcinoma cases for immunohistochemical study and survival analysis between 1996 and 2004 from the Chi Mei Medical Center archives. For the initial validation, which focused on identifying the most significant among the candidate genes, we randomly selected 50 UBUCs and 50 urinary tract urothelial carcinomas (UTUCs) as the pilot batch of cases. We further evaluated the gene demonstrating greatest clinical significance in an independent cohort, as previously described [@B11]. The independent cohort included a total of 635 consecutively treated, well-characterized cases: 340 tumors originating from the UT and 295 arising from the UB. All patients received nephroureterectomy and excision of the bladder with regional lymph node dissection. Of these cases, UBUC patients with pT3 or pT4 stage tumors or with nodal involvement received cisplatin-based post-operative adjuvant chemotherapy, but patients with renal insufficiency obtained carboplatin. However, only 29 of the 106 UTUC patients with pT3 or pT4 stage tumors or nodal involvement received post-operative adjuvant chemotherapy. In addition, neo-adjuvant chemotherapy was not introduced to the patients with UBUC or UTUC in our cohort. The criteria for clinicopathological evaluation were essentially identical to those in our previous work [@B11]. Two pathologists (P.I.L & C.F.L) re-evaluated hematoxylin-eosin sections of all cases.

Immunohistochemical staining
----------------------------

Following histological review, tissue blocks containing the most invasive area of each case were selected for immunohistochemical study. We cut representative tissue sections of 4-μm thickness onto precoated slides from the paraffin-embedded tissue blocks, succeeded by deparaffinization, rehydration, antigen retrieval, and blockage of endogenous peroxidase. Endogenous peroxidase was buffered with saline for 15 minutes and subsequently incubated with a primary antibody targeting CALD1 (1:100, C-19, Santa Cruz) or SPOCK1 (1:200, 102D1, Santa Cruz) for one hour. We detected primary antibodies using the DAKO ChemMate EnVision Kit (K5001, Carpinteria, CA, USA). The presence of brown chromogen in the cytoplasm of target cells indicated positive immunoreactivity. The quality of immunostaining was ensured by a negative control incubated without the primary antibody.

Interpretation and scoring of immunohistochemistry
--------------------------------------------------

Two pathologists (P.I.L & C.F.L) appraised the immunohistochemistry without prior knowledge of clinical and follow-up data. Immunoreactivity was estimated with a combination of the percentage and intensity of positively stained tumor cytoplasm in order to generate the H-score, which was calculated by the following equation: H-score=∑Pi(i +1), where i is the intensity of stained tumor cells (0 to 3+), and Pi is the percentage of stained tumor cells for each intensity varying from 0% to 100%. This formula produces a score range from 100-400, where 100 equals 100% of tumor cells showing negative results and 400 equals 100% of tumor cells strongly stained (3+) [@B12], [@B13].

Real-time RT-PCR
----------------

Since *SPOCK1* was identified as the most significantly altered gene, its transcript level was further determined in a collection of snap-frozen samples containing high percentage (no less than 70%) of tumor elements consisting of 27 UBUCs and 27 UTUCs, respectively. For this goal, total RNAs were extracted, quantified, and submitted for reverse-transcription. Using pre-designed TaqMan assay reagents (Applied Biosystems), we measured mRNA abundance of *SPOCK1* (Hs00270274_m1) with the ABI StepOnePlus™ System. The fold expression of *SPOCK1* relative to normal urothelium was calculated by comparative Ct method, after normalization to *POLR2A* (Hs01108291_m1) as the internal control.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS V.14.0 software (SPSS Inc. Chicago, IL, USA). The median H-score of immunohistochemistry for SPOCK1 was the cutoff to dichotomize the study cohort, separating cases into high expression and low expression groups. We employed the chi-square test to compare SPOCK1 expression status and various clinicopathological parameters. The end points analyzed were disease-specific survival (DSS) and metastasis-free survival (MeFS), calculated from the date of curative surgery to the date an event developed. Patients lost to follow-up were censored on the final follow-up date. We plotted survival curves using the Kaplan-Meier method, and evaluated prognostic differences between groups using the log-rank test. Parameters demonstrating *P* values less than 0.05 in univariate analysis were subsequently enrolled into multivariate tests using the Cox proportional hazards model. For all analyses, two-sided tests of significance with *P*\<0.05 were considered significant.

Results
=======

*CALD1*,*SPOCK1*,*SCG2, IGF1*and *CEECAM1* were identified as significant differentially upregulated transcripts implicated in cell motility in UC
--------------------------------------------------------------------------------------------------------------------------------------------------

From the transcriptomic profiles of GSE31684, we found 109 probes covering 52 transcripts associated with cell motility (GO:0048870). Of these, only seven probes covering five genes showed significant differential expression associated with both increments of primary tumor stage and the presence of distal metastasis (**Fig. [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}**). Of these, the upregulated *CALD1* and *SPOCK1* were more significant and met the selection criteria. Of the candidate genes, *CALD1* was the most significantly upregulated with increments of primary tumor status, showing a log2 ratio of 1.6569 fold. *SPOCK1* upregulation was most significantly associated with the presence of distal metastasis (log2 ratio of 0.843).

SPOCK1 expression was most significantly associated with tumor aggressiveness in genes associated with cell motility
--------------------------------------------------------------------------------------------------------------------

In the pilot batch of cases for initial validation, SPOCK1 but not CALD1 overexpression was significantly associated with both primary tumor status (UTUC, *P*=0.004; UBUC, *P*=0.009) and nodal metastasis (UTUC, *P*=0.037; UBUC, *P*=0.042) (**Table [S1](#SM1){ref-type="supplementary-material"}**). Moreover, SPOCK1 was the most significant candidate that predicted inferior DSS (UTUC, *P*=0.0002; UBUC, *P*=0.0017) and worse MeFS (UTUC, *P*\<0.0001; UBUC, *P*=0.0006) (**Table [S2](#SM1){ref-type="supplementary-material"}**).

*SPOCK1* mRNA expression is positively associated with higher pT status in both UTUC and UBUC
---------------------------------------------------------------------------------------------

In the 27 UTUCs and 27 UBUCs tested, *SPOCK1* mRNA expression was significantly upregulated with higher pT status in both UTUC (*P*=0.002) and UBUC (*P*=0.001), suggesting that it plays a role in tumor progression (**Fig. [2](#F2){ref-type="fig"}**).

Clinicopathological findings for UTUC
-------------------------------------

The clinicopathological features of the UTUC patients are listed in **Table [2](#T2){ref-type="table"}**. The disease showed no predilection for either sex. The median age at diagnosis was 68 years, ranging from 34 to 87 years. Sixty-two patients (18.2%) suffered from multifocal tumors, and 49 (14.4%) had tumors involving both the renal pelvis and ureter. The majority of cases (n=284, 83.5%) were of high histological grade. Advanced pT stage (pT2-T4) was seen in 159 cases (46.8%). Around one-half of the cases (n=167, 49.1%) showed mitotic activity. Vascular invasion and perineurial invasion were noted in 106 cases (31.2%) and 19 cases (5.9%), respectively. Nodal metastasis was observed in 28 patients (8.2%).

Clinicopathological findings for UBUC
-------------------------------------

UBUC patients were predominantly male (n=216, 73.2%) and older than 65 years (n=174, 59.0%). As outlined in **Table [2](#T2){ref-type="table"}**, most (n=239, 81%) were of high histological grade, with 123 (41.7%) in advanced stages (pT2-T4) at initial diagnosis. One hundred and fifty-six cases (52.9%) showed high mitotic activity (≥ 10/10HPFs). Lymph node metastasis was detected in 23.6% of patients (n=29). Vascular invasion was evident in 49 cases (16.6%) and perineurial invasion in 20 cases (6.8%).

Correlation of SPOCK1 immunoreactivity with parameters in UTUC and UBUC
-----------------------------------------------------------------------

SPOCK1 demonstrates variable cytoplasmic expression in carcinoma cells of both the UT and UB, with median H-scores of 260 (range, 110-380) and 285 (range, 115-375) respectively. In contrast, the expression level of SPOCK1 is very low in normal urothelium, with H-scores ranging from 100 to 140. After dichotomizing the tumors into those with low and high SPOCK1 expression, as illustrated in **Table [2](#T2){ref-type="table"}**, we found increased SPOCK1 expression was significantly associated with increments of pT status (*P*\<0.001), lymph node metastasis (UTUC, *P*=0.006; UBUC, *P*=0.033), higher histological grade (UTUC, *P*\<0.001; UBUC, *P*\<0.001), vascular invasion (UTUC, *P*\<0.001; UBUC, *P*\<0.001), perineurial invasion (UTUC, *P*\<0.001; UBUC, *P*=0.001) and frequent mitosis (UTUC, *P*\<0.001; UBUC, *P*=0.001) in urothelial carcinomas of the two locations. These findings point to a role for SPOCK1 in the progression of UC.

Survival analysis for UTUC
--------------------------

Follow-up information, with duration ranging from 1 to 176 months (median, 38), was available for all patients. Univariate and multivariate analyses of the association between clinical outcomes and various clinicopathological features of UTUC cases are summarized in **Table [3](#T3){ref-type="table"}**. Both univariate and multivariate analysis revealed that poor DSS was significantly associated with multifocality (*P*=0.0042 and *P*=0.006, respectively), advanced pT (*P*\<0.0001 and *P*=0.010, respectively), lymph node metastasis (*P*\<0.0001 and *P*\<0.0001, respectively), high histological grade (*P*=0.0171 and *P*=0.044, respectively), perineurial invasion (*P*\<0.0001 and *P*=0.002, respectively), and high SPOCK1 expression (*P*\<0.0001 and *P*=0.031, respectively). Similar results were also seen for MeFS, excluding primary tumor and histological grade. However, vascular invasion in UTUC was also independently and significantly associated with worse MeFS (*P*\<0.0001 and *P*=0.015, respectively).

Survival analysis for UBUC
--------------------------

Follow-up information is available for all patients, with a median duration of 23.1 months (range, 1-109). As illustrated in **Table [4](#T4){ref-type="table"}**, in multivariate analyses, pT stage, mitotic rate, and SPOCK1 expression were significantly associated with both inferior DSS (*P*\<0.001, *P*=0.015 and *P*\<0.001, respectively) and MeFS (*P*=0.008, *P*=0.009 and *P*\<0.001, respectively). Perineurial invasion was also predictive of DSS.

Prognostic significance of SPOCK1 expression in UC
--------------------------------------------------

In the univariate analyses (**Table [3](#T3){ref-type="table"}**), patients with UTUC showing high SPOCK1 expression had significantly worse DSS (*P*\<0.0001, **Fig. [4](#F4){ref-type="fig"}A**) and MeFS (*P*\<0.0001, **Fig. [4](#F4){ref-type="fig"}B**). Similar results were also noted for patients with UBUC (**Table [4](#T4){ref-type="table"}**, **Fig. [4](#F4){ref-type="fig"}C, and Fig. [4](#F4){ref-type="fig"}D**). Of regard, SPOCK1 overexpression remained an independent prognosticator portending poor DSS and MeFS for both UTUC and UBUC patients (**Table [3](#T3){ref-type="table"}**and**Table [4](#T4){ref-type="table"}**).

Discussions
===========

Interesting in markers of UC prognosis, the study identified five significantly expressed genes related to cell motility due to that invasion and metastasis had been suggested associating with adverse outcome in patients with UC. Among those genes, both *CALD1* and *SPOCK1* were expressed significantly, fitting with a log2 ratio over 1 and 0.5 fold in primary tumor status and distal metastasis, respectively (**Table [1](#T1){ref-type="table"}**). *CALD1* is involved in cell motility through the organization of the actin skeleton and actin/myosin-dependent contractility [@B14]. SPOCK1, a highly conserved, multidomain proteoglycan in the extracellular matrix, could play a role in modulating protease activity [@B7]. In the pilot study, only SPOCK1 exhibited crucial differences in primary tumor status, nodal metastasis and survival (**Table [S1](#SM1){ref-type="supplementary-material"}, Table [S2](#SM1){ref-type="supplementary-material"}**), implying its importance in UC aggressiveness compared to CALD1. In Fig. [2](#F2){ref-type="fig"}, higher pT was related to higher *SPOCK1* mRNA expression. In addition, worse DSSs and MeFSs were associated with higher SPOCK1expression (Fig. [4](#F4){ref-type="fig"}). Aforementioned data may support the probable utility of SPOCK1 as a poor prognostic factor of UC.

SPOCK1, known as testican-1, was originally identified in seminal plasma [@B15]. The expression of *SPOCK1* mRNA in humans has been noted in various tissues with the highest levels in the brain, the prostate, and the testis [@B16]. A study showed that a *de novo* missense change in *SPOCK1* identified by whole exon sequencing might relate to developmental delay, microcephaly and agenesis of the corpus callosum, leading to the hypothesis that *SPOCK1* plays a critical role in neurogenesis [@B17]. SPOCK1 contains three domains *viz.*, a follistatin domain, an extracellular calcium-binding domain, and a thyroglobulin type-1 domain, which possess functions of regulating metalloproteinase, and cysteine and serine proteases [@B16], [@B17]. In a genome-wide association study of age at menarche, *SPOCK1* was identified as a novel gene and arousing speculation about the underlying mechanism regarding its influence on matrix metalloproteinase-2 [@B18].

Furthermore, in the study of gastrointestinal neuroendocrine carcinomas, *SPOCK1* was identified by microarray analysis as a candidate related to metastasis and was expressed 100-fold more in tumor material than in normal ileum [@B19]. Upregulated *SPOCK1* has also been identified in lung cancer [@B20], HCC [@B10], and gallbladder cancer [@B21]. The clinical significance of SPOCK1 in lung cancer was correlated with metastasis and silencing of *SPOCK1* in cell study inhibited lung cancer cell invasion *in vitro*[@B20]. In addition, the tumorigenic ability of *SPOCK1* in HCC was investigated in a xenograft mouse model with promising results [@B10]. In our findings, SPOCK1 was also expressed more strongly in tumor tissues than in normal ones (**Fig. [3](#F3){ref-type="fig"}**). Moreover, higher expression of SPOCK1 is also related to positive nodal metastasis and presence of vascular and perineural invasion (**Table [2](#T2){ref-type="table"}**), suggesting that it may have a role in UC invasion and metastasis, as noted with other cancers.

Also, altered composition of the extracellular matrix (ECM) is important in cancer. Epithelial-mesenchymal transition (EMT) involves changes in the cells themselves and in their surrounding microenvironment. Many studies support that obtaining epithelial-mesenchymal transition (EMT) features correlates with poor outcome among patients with various cancer types, including colorectal [@B22], lung [@B23], breast [@B24], and bladder cancer [@B25]. *SPOCK1*, the ECM gene, was not only overexpressed in prostate cancer tissues compared to benign samples, but also indicated a tendency toward earlier recurrence [@B26]. Interestingly, our study showed that high levels of SPOCK1 expression are correlated to poor DSS and MFS in UC in univariate log-rank tests (**Table [3](#T3){ref-type="table"}, Table [4](#T4){ref-type="table"}**). In vivo studies of lung cancer demonstrated that SPOCK1 is not only associated with metastasis and also induces EMT [@B20]. Aforementioned facts may suggest that in UC, SPOCK1 may be a novel prognostic factor and may participate in tumor invasion and metastasis through involvement in the process of EMT.

Moreover, evading apoptosis is another capability that characterizes cancer cells [@B27]. One study of GBC found that SPOCK1 not only promotes cell migration and invasion by inducing EMT but also inhibits apoptosis [@B21]. The PI3 kinase-ATK/PKB pathway is important in affecting apoptosis [@B27]. In a mouse model, this signal pathway was demonstrated to have role in upper tract of UC [@B28]. The PI3 kinase-ATK/PKB pathway is also a downstream kinase pathway triggered by *FGFR3*, one of the important molecules involving bladder of UC [@B29]. Furthermore, higher SPOCK1 expression was correlated with higher mitotic rate, as shown in Table-[2](#T2){ref-type="table"}, indicating that the adverse prognosis associated with high SPOCK1 expression may also relate to cell proliferation.

In conclusion, we present that higher SPOCK1 is related to unfavorable clinicopathological parameters and shorter survival in UC patients. Hypothetically, SPOCK1 may play an important role in the EMT of UC, and may be crucial in UC metastasis. Probably, SPOCK1 may also take a part in evading apoptosis through cell proliferation. This study suggested that SPOCK1 could be an independent prognostic factor in UC, might serve as an oncogene and would be a candidate of target therapy.
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![Analysis of gene expression in urothelial carcinomas of the bladders from a published transcriptomic dataset (GSE31684). Clustering analysis of genes focusing on cell motility (GO:0048870) showed upregulation of *IGF1*, *CALD1*, *CEECAM*, *SPOCK1* and *SCG2* were more significantly associated with both higher primary tumor status (pT) and distal metastasis. Specimens from high pT (blue lines) and low pT (yellow lines) are indicated on top of the heatmap, and upregulation and downregulation of genes are illustrated as a spectrum of brightness of red and green, respectively, with those unaltered coded as black.](jcav07p0467g001){#F1}

![Quantitative real-time RT-PCR analysis revealed that *SPOCK1* mRNA expression was significantly upregulated in urinary tract urothelial carcinomas (UTUCs, *left* panel) and urinary bladder urothelial carcinomas (UBUCs, *right* panel) with higher primary tumor status.](jcav07p0467g002){#F2}

![Immunohistochemical staining for SPOCK1 in representative urothelium. Compared with surrounding non-tumorous tissues (A), the tumor tissues have significantly escalated immunostaining for SPOCK1 from non-invasive (B), superficially invasive (C) and deeply invasive urithelial carcinoma (D).](jcav07p0467g003){#F3}

![Survival analysis plotted by Kaplan-Meier curves. By log-rank test, high expression of SPOCK1 is predictive for inferior disease-free survival in both UTUC and UBUC (A, C) and for poor metastasis-free survival in both UTUC and UBUC (B, D).](jcav07p0467g004){#F4}

###### 

Summary of differentially expressed genes associated with Cell Motility (GO: 0048870) and showed positive associations to cancer invasiveness and metastasis in the transcriptome of urothelial carcinoma of urinary bladder (GSE31684).

  Probe          Comparing T2-4 to Ta-T1   Comparing Meta. to Non-Meta.^\#^   Gene Symbol   Biological Process   Molecular Function                                                                                                                                                                                                                                                                                                                                                                 
  -------------- ------------------------- ---------------------------------- ------------- -------------------- -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  201617_x\_at   1.6569                    \<0.0001                           0.6623        0.0085               *CALD1*              cell motility, muscle contraction                                                                                                                                                                                                                                                                                                                             actin binding, calmodulin binding, myosin binding, tropomyosin binding
  202363_at      1.1471                    0.0003                             0.843         0.0005               *SPOCK1*             cell adhesion, cell motility, cell proliferation, multicellular organismal development, nervous system development                                                                                                                                                                                                                                            calcium ion binding
  204035_at      0.5489                    0.0071                             0.519         0.0009               *SCG2*               MAPKKK cascade, angiogenesis, cell motility, endothelial cell migration, eosinophil chemotaxis, induction of positive chemotaxis, inflammatory response, intracellular signaling cascade, negative regulation of apoptosis, negative regulation of endothelial cell proliferation, positive regulation of endothelial cell proliferation, protein secretion   calcium ion binding, chemoattractant activity, cytokine activity
  209540_at      0.7559                    0.0038                             0.6879        0.0005               *IGF1*               DNA replication, Ras protein signal transduction, cell motility, glycolate metabolic process, muscle development, positive regulation of cell proliferation, regulation of steroid hormone receptor signaling pathway, sensory perception of sound, signal transduction, skeletal development                                                                 growth factor activity, hormone activity, insulin-like growth factor receptor binding, prothoracicotrophic hormone activity
  209541_at      0.8353                    0.0015                             0.7105        0.0005               *IGF1*               DNA replication, Ras protein signal transduction, cell motility, glycolate metabolic process, muscle development, positive regulation of cell proliferation, regulation of steroid hormone receptor signaling pathway, sensory perception of sound, signal transduction, skeletal development                                                                 growth factor activity, hormone activity, insulin-like growth factor receptor binding, prothoracicotrophic hormone activity
  209542_x\_at   0.3483                    0.0058                             0.3631        0.0001               *IGF1*               DNA replication, Ras protein signal transduction, cell motility, glycolate metabolic process, muscle development, positive regulation of cell proliferation, regulation of steroid hormone receptor signaling pathway, sensory perception of sound, signal transduction, skeletal development                                                                 growth factor activity, hormone activity, insulin-like growth factor receptor binding, prothoracicotrophic hormone activity
  224794_s\_at   1.0792                    \<0.0001                           0.4795        0.0067               *CEECAM1*            cell adhesion, cell motility, leukocyte adhesion, lipopolysaccharide biosynthetic process                                                                                                                                                                                                                                                                     oxidoreductase activity; acting on single donors with incorporation of molecular oxygen; incorporation of two atoms of oxygen, procollagen-lysine 5-dioxygenase activity

\#, Meta., distal metastasis developed during follow-up; Non-Meta.: no metastatic event developed.

###### 

Correlations between SPOCK1 Expression and other important clinicopathological parameters in urothelial carcinomas.

  Parameter                                     Category        Upper Urinary Tract Urothelial Carcinoma   Urinary Bladder Urothelial Carcinoma                                                               
  --------------------------------------------- --------------- ------------------------------------------ -------------------------------------- ------------- ----------- ----- ------------- ------------- -----------
  Gender^&^                                     Male            158                                        82                                     76            0.514       216   105           111           0.489
  Female                                        182             88                                         94                                                   79          42    37                          
  Age (years)^\#^                                               340                                        65.16±10.91                            66.00±8.76    0.961       295   65.27±13.02   66.81±11.35   0.543
  Tumor location^&^                             Renal pelvis    141                                        66                                     75            0.194       \-    \-            \-            \-
  Ureter                                        150             83                                         67                                                   \-          \-    \-            \-            
  Renal pelvis & ureter                         49              21                                         28                                                   \-          \-    \-            \-            
  Multifocality^&^                              Single          278                                        143                                    135           0.261       \-    \-            \-            \-
  Multifocal                                    62              27                                         35                                                   \-          \-    \-            \-            
  Primary tumor (T)^&^                          Ta              89                                         61                                     28            \<0.001\*   84    70            14            \<0.001\*
  T1                                            92              57                                         35                                                   88          42    46                          
  T2-T4                                         159             52                                         107                                                  123         35    88                          
  Nodal metastasis^&^                           Negative (N0)   312                                        163                                    149           0.006\*     266   138           128           0.033\*
  Positive (N1-N2)                              28              7                                          21                                                   29          9     20                          
  Histological grade ^&^                        Low grade       56                                         41                                     15            \<0.001\*   56    46            10            \<0.001\*
  High grade                                    284             129                                        155                                                  239         101   138                         
  Vascular invasion^&^                          Absent          234                                        148                                    86            \<0.001\*   246   140           106           \<0.001\*
  Present                                       106             22                                         84                                                   49          7     42                          
  Perineural invasion^&^                        Absent          321                                        169                                    152           \<0.001\*   275   144           131           0.001\*
  Present                                       19              1                                          18                                                   20          3     17                          
  Mitotic rate (per 10 high power fields)^\#^                   340                                        10.63±12.07                            13.99±12.30   \<0.001\*   295   12.41±13.89   16.39±13.95   0.001\*

&, Chi-Square test; \#, Mann-Whitney U test; \* Statistically significant.

###### 

Univariate log-rank and multivariate analyses for Disease-specific and Metastasis-free Survivals in Upper urinary tract urothelial carcinoma

  Parameter                                 Category        Case No.   Disease-specific Survival   Metastasis-free Survival                                                                         
  ----------------------------------------- --------------- ---------- --------------------------- -------------------------- ------------- ----- ----------- ---- ------------ -------------- ---- ---------
  Gender                                    Male            158        28                          0.9301                     \-            \-    \-          32   0.7904       \-             \-   \-
  Female                                    182             33                                     \-                         \-            \-    38               \-           \-             \-   
  Age (years)                               \< 65           138        26                          0.8660                     \-            \-    \-          30   0.8470       \-             \-   \-
  ≥ 65                                      202             35                                     \-                         \-            \-    40               \-           \-             \-   
  Tumor side                                Right           177        34                          0.7188                     \-            \-    \-          38   0.3074       \-             \-   \-
  Left                                      154             26                                     \-                         \-            \-    32               \-           \-             \-   
  Bilateral                                 9               1                                      \-                         \-            \-    0                \-           \-             \-   
  Tumor location                            Renal pelvis    141        24                          0.0120\*                   1             \-    0.912       31   0.0659       \-             \-   \-
  Ureter                                    150             22                                     0.794                      0.421-1.500         25               \-           \-             \-   
  Renal pelvis & ureter                     49              15                                     1.641                      0.452-5.955         14               \-           \-                  
  Multifocality                             Single          273        48                          0.0042\*                   1             *-*   0.006\*     52   0.0196\*     1              \-   0.002\*
  Multifocal                                62              18                                     2.809                      1.355-6.162         18               2.383        1.369-4.149         
  Primary tumor (T)                         Ta              89         2                           \<0.0001\*                 1             \-    0.010\*     4    \<0.0001\*   1              \-   0.106
  T1                                        92              9                                      1.832                      0.976-4.202         15               2.641        0.844-8.264         
  T2-T4                                     159             50                                     6.173                      1.359-27.78         51               2.867        0.905-9.082         
  Nodal metastasis                          Negative (N0)   312        42                          \<0.0001\*                 1             \-    \<0.001\*   55   \<0.0001\*   1              \-   0.001\*
  Positive (N1-N2)                          28              19                                     4.971                      2.657-9.301         15               2.932        1.575-5.457         
  Histological grade                        Low grade       56         4                           0.0171\*                   1             \-    0.044\*     3    0.0019\*     1              \-   0.058
  High grade                                284             57                                     3.182                      1.034-9.788         67               3.288        0.961-11.249        
  Vascular invasion                         Absent          234        24                          \<0.0001\*                 1             \-    0.351       26   \<0.0001\*   1              \-   0.015\*
  Present                                   106             37                                     1.337                      0.726-2.463         44               2.184        1.162-4.105         
  Perineural invasion                       Absent          321        50                          \<0.0001\*                 1             \-    0.002\*     61   \<0.0001\*   1              \-   0.018\*
  Present                                   19              11                                     3.335                      1.556-7.150   \--   9                2.485        1.172-5.210         
  Mitotic rate (per 10 high power fields)   \< 10           173        27                          0.1268                     \-            \-    \-          30   0.0581       \-             \-   \-
  \>= 10                                    167             34                                     \-                         \-            \-    40               \-           \-             \-   
  SPOCK1 expression                         Low             170        10                          \<0.0001\*                 1             \-    0.031\*     14   \<0.0001\*   1              \-   0.039\*
  High                                      170             50                                     2.278                      1.080-4.803         56               2.016        1.037-3.916         

\* Statistically significant

###### 

Univariate log-rank and multivariate analyses for Disease-specific and Metastasis-free Survivals in urinary bladder urothelial carcinoma.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                 Category        Case No.   Disease-specific Survival   Metastasis-free Survival                                                                          
  ----------------------------------------- --------------- ---------- --------------------------- -------------------------- --------------- ---- ----------- ---- ------------ -------------- ---- -----------
  Gender                                    Male            216        41                          0.4906                     \-              \-   \-          61   0.2745       \-             \-   \-

  Female                                    79              11                                     \-                         \-              \-   16               \-           \-             \-   

  Age (years)                               \< 65           121        17                          0.1315                     \-              \-   \-          32   0.8786       \-             \-   \-

  ≥ 65                                      174             35                                     \-                         \-              \-   45                                                

  Primary\                                  Ta              84         1                           \<0.0001\*                 1               \-   \<0.001\*   4    \<0.0001\*   1              \-   0.008\*
  tumor (T)                                                                                                                                                                                          

  T1                                        88              9                                      2.823                      0.307-25.968         23               2.595        0.757-8.891         

  T2-T4                                     123             42                                     12.821                     1.459-112.681        50               4.363        1.271-14.977        

  Nodal\                                    Negative (N0)   266        41                          0.0001\*                   1               \-   0.444       61   \<0.0001\*   1              \-   0.009\*
  metastasis                                                                                                                                                                                         

  Positive (N1-N2)                          29              11                                     1.315                      0.652-2.650          16               2.216        1.217-4.034         

  Histological grade                        Low grade       56         2                           0.0016\*                   1               \-   0.899       5    0.0007\*     1              \-   0.891

  High grade                                239             50                                     1.101                      0.248-4.880          72               1.073        0.393-2.927         

  Vascular\                                 Absent          246        37                          0.0010\*                   1               \-   0.032\*     54   \<0.0001\*   1              \-   0.600
  invasion                                                                                                                                                                                           

  Present                                   49              15                                     2.096                      1.064-4.132          23               1.167        0.654-2.083         

  Perineural\                               Absent          275        44                          \<0.0001\*                 1               \-   0.025\*     67   0.0003\*     1              \-   0.161
  invasion                                                                                                                                                                                           

  Present                                   20              8                                      2.601                      1.127-6.004          10               1.696        0.810-3.554         

  Mitotic rate (per 10 high power fields)   \< 10           139        12                          0.0001\*                   1               \-   0.015\*     23   \<0.0002\*   1              \-   0.009\*

  \>= 10                                    156             40                                     2.279                      1.170-4.439          54               1.958        1.181-3.247         

  SPOCK1\                                   Low             147        5                           \<0.0001\*                 1               \-   \<0.001\*   13   \<0.0001\*   1              \-   \<0.001\*
  expression                                                                                                                                                                                         

  High                                      148             47                                     6.965                      2.725-17.801         64               4.675        2.515-8.690         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Statistically significant
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